Carcinogenesis, Vol. 21, No. 11, 1941-1945,
November 2000
© 2000 Oxford University Press
Cancer Biology |
Galectin-3 mediates genistein-induced G2/M arrest and inhibits apoptosis
1 Department of Pathology and
2 Breast Cancer Program, Barbara Ann Karmanos Cancer Institute, Wayne State University, School of Medicine, Detroit, MI 48201, USA and
3 Department of Anesthesiology, Ajou University School of Medicine, Suwon, Korea
Many recent studies have focused on potential chemopreventive activities of dietary genistein, a natural isoflavonoid compound found in soy products. Genistein has been implicated in anticancer activities, including differentiation, apoptosis, inhibition of cell growth and inhibition of angiogenesis. In previous studies, genistein was shown to induce apoptosis and cell cycle arrest at G2/M in several cancer cell lines in vitro, which is associated with induction of p21WAF1/CIP1, a universal inhibitor of cyclin-dependent kinases. At present, the molecular basis for diverse genistein-mediated cellular responses is largely unknown. In the present study, we investigated whether galectin-3, an anti-apoptotic gene product, regulates genistein-mediated cellular responses. We show that genistein effectively induces apoptosis without detectable cell cycle arrest in BT549, a human breast epithelial cell line which does not express galectin-3 at a detectable level. In galectin-3 transfected BT549 cells, genistein induced cell cycle arrest at the G2/M phase without apoptosis induction. Interestingly, genistein induces p21WAF1/CIP1 expression in galectin-3-expressing BT549 cells, but not in control BT549 cells undergoing apoptosis. Collectively, the results of the present study suggest that galectin-3, at least in part, is a critical determinant for genistein-mediated cell cycle arrest and apoptosis, and genistein induction of p21WAF1/CIP1 is associated with cell cycle arrest, but not required for apoptosis induction.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
V. G. Prieto, A. A. Mourad-Zeidan, V. Melnikova, M. M. Johnson, A. Lopez, A. H. Diwan, A. J.F. Lazar, S. S. Shen, P. S. Zhang, J. A. Reed, et al. Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma. Clin. Cancer Res., November 15, 2006; 12(22): 6709 - 6715. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Fukumori, N. Oka, Y. Takenaka, P. Nangia-Makker, E. Elsamman, T. Kasai, M. Shono, H.-o. Kanayama, J. Ellerhorst, R. Lotan, et al. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res., March 15, 2006; 66(6): 3114 - 3119. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Oka, S. Nakahara, Y. Takenaka, T. Fukumori, V. Hogan, H.-o. Kanayama, T. Yanagawa, and A. Raz Galectin-3 Inhibits Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis by Activating Akt in Human Bladder Carcinoma Cells Cancer Res., September 1, 2005; 65(17): 7546 - 7553. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shimura, Y. Takenaka, T. Fukumori, S. Tsutsumi, K. Okada, V. Hogan, A. Kikuchi, H. Kuwano, and A. Raz Implication of Galectin-3 in Wnt Signaling Cancer Res., May 1, 2005; 65(9): 3535 - 3537. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. W. Stitt, C. McGoldrick, A. Rice-McCaldin, D. R. McCance, J. V. Glenn, D. K. Hsu, F.-T. Liu, S. R. Thorpe, and T. A. Gardiner Impaired Retinal Angiogenesis in Diabetes: Role of Advanced Glycation End Products and Galectin-3 Diabetes, March 1, 2005; 54(3): 785 - 794. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Takenaka, T. Fukumori, T. Yoshii, N. Oka, H. Inohara, H.-R. C. Kim, R. S. Bresalier, and A. Raz Nuclear Export of Phosphorylated Galectin-3 Regulates Its Antiapoptotic Activity in Response to Chemotherapeutic Drugs Mol. Cell. Biol., May 15, 2004; 24(10): 4395 - 4406. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Fukumori, Y. Takenaka, T. Yoshii, H.-R. C. Kim, V. Hogan, H. Inohara, S. Kagawa, and A. Raz CD29 and CD7 Mediate Galectin-3-Induced Type II T-Cell Apoptosis Cancer Res., December 1, 2003; 63(23): 8302 - 8311. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. John, H. Leffler, B. Kahl-Knutsson, I. Svensson, and G. A. Jarvis Truncated Galectin-3 Inhibits Tumor Growth and Metastasis in Orthotopic Nude Mouse Model of Human Breast Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2374 - 2383. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Gartel and A. L. Tyner The Role of the Cyclin-dependent Kinase Inhibitor p21 in Apoptosis Mol. Cancer Ther., June 1, 2002; 1(8): 639 - 649. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Yu, R. L. Finley Jr., A. Raz, and H.-R. C. Kim Galectin-3 Translocates to the Perinuclear Membranes and Inhibits Cytochrome c Release from the Mitochondria. A ROLE FOR SYNEXIN IN GALECTIN-3 TRANSLOCATION J. Biol. Chem., May 3, 2002; 277(18): 15819 - 15827. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. K. Song, T. R. Billiar, and Y. J. Lee Role of Galectin-3 in Breast Cancer Metastasis : Involvement of Nitric Oxide Am. J. Pathol., March 1, 2002; 160(3): 1069 - 1075. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Messina and C. L. Loprinzi Soy for Breast Cancer Survivors: A Critical Review of the Literature J. Nutr., November 1, 2001; 131(11): 3095S - 3108. [Abstract] [Full Text] [PDF] |
||||







